<clinical_study>
<study_id>
<org_name>
  QMedAB
</org_name>
<org_full_name>
  Q-Med AB
</org_full_name>
<org_study_id>
  35GA1203
</org_study_id>
<nct_id>
  NCT01753830
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis
</textblock>
</brief_title>
<official_title>
<textblock>
  A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane&#174; Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Q-Med AB
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of the study is to determine whether a single intra-articular injection of Durolane is superior to a single injection of PBS for the relief of joint pain in patients with osteoarthritis of the knee.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
 Recruiting 
</status>
<date>
2013-01 
</date>
</status_block>
<start_date>
<date>
  2012-12
</date>
</start_date>
<primary_compl_date
 type="Anticipated"
>
<date>
  2014-08
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Double Blind (Subject, Outcomes Assessor)
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Outcome Measures in Rheumatology Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) Response
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  WOMAC Physical Function score
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life questionnaire
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Physical Global Evaluation
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Patient Global Evaluation
</measure>
<time_frame>
  Up to 30 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Anticipated"
>
  340
</enrollment>
<condition>
  Knee Osteoarthritis
</condition>
<arm_group>
<arm_group_label>
  Durolane
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Single intraarticular injection of Durolane
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  PBS
</arm_group_label>
<arm_type>
  Placebo Comparator
</arm_type>
<description>
<textblock>
  Single intraarticular injection of PBS
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Device
</intervent_type>
<primary_name>
  Durolane
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  Durolane
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Device
</intervent_type>
<primary_name>
  PBS
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  PBS
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Body Mass Index (BMI) &#8804; 35 kg/m2
    - Symptomatic OA of the knee
    - K L severity grade 1 or 2
    - If bilateral OA, contralateral knee K L severity grade 0 or 1
 
  Exclusion Criteria:
    - Has clinically apparent tense effusion of the index knee
    - Has had surgery on the symptomatic knee within the previous 12 months or arthroscopy in the index knee in the past 3 months
    - Has any painful orthopedic disorders of the back or hip
    - Has a joint disorder other than osteoarthritis in the index knee
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  40 Years
</minimum_age>
<maximum_age>
  80 Years
</maximum_age>
</eligibility>
<location>
<facility>
<name>
  Tucson Orthopaedic Institute
</name>
<address>
<city>
  Tucson
</city>
<state>
  Arizona
</state>
<zip>
  85712
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
 Recruiting 
</status>
<contact>
<name>
  Nebojsa Skrepnik, MD, PhD
</name>
<phone>
  520-784-6481
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Nebojsa Skrepnik, MD, PhD
</name>
</contact>
</location>
<keyword>
  Double-blind
</keyword>
<keyword>
  Randomized
</keyword>
<keyword>
  Intraarticular injection
</keyword>
<keyword>
  Hyaluronic acid
</keyword>
<keyword>
  Placebo
</keyword>
<keyword>
  Knee osteoarthritis
</keyword>
<initial_release_date>
  2012-12-12
</initial_release_date>
<last_release_date>
2013-01-11 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
